Navigation Links
Burrill & Company Reacquires Burrill Life Sciences Media Group LLC
Date:12/12/2007

SAN FRANCISCO, Dec. 12 /PRNewswire/ -- Burrill & Company announces today its reacquisition of the Burrill Life Sciences Media Group, LLC (including The Journal of Life Sciences) from Nielsen Business Media, Inc. Terms have not been disclosed.

About Burrill & Company

Founded in 1994, Burrill & Company is a San Francisco-based global leader in life sciences whose principal activities are in Venture Capital, Merchant Banking and Media. The Burrill family of venture capital funds has over $950 million under management and its merchant banking business is one of the industry leaders in life sciences transactions.

Burrill publishes a range of industry intelligence reports and newsletters including: The Journal of Life Sciences, in association with the California Healthcare Institute, The Personalized Medicine Report, The Stem Cell Report, Canadian Biotech News and the Burrill Biotechnology Intelligence Report Quarterly. Its flagship publication is the "State of the Industry." The 22nd edition, entitled Biotech 2008: A Clear Vision to 2020 will be published in January 2008. These publications provide an up-to-date resource for the latest insight, intelligence and information regarding the life sciences industry.


'/>"/>
SOURCE Burrill & Company
Copyright©2007 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Biotech Finishes on a High in August, Burrill Report Says
2. Owner and Operator of Florida Durable Medical Equipment Company Convicted of Medicare Fraud
3. Claim Filed Against the Company and Nine Other Defendants in the Haifa Magistrates Court
4. Cleveland-based Health Care Tech Company Within3 Names New CEO
5. Three Batesville Casket Company Production Facilities Honored for Manufacturing Expertise by National Organizations
6. iCAD to Present at William Blair & Company Small-Cap Growth Stock Conference
7. Elliott Extremely Dissatisfied With Genzyme Bid for Bioenvision; Believes Offer Significantly Undervalues Company
8. Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts Meeting September 28, 2007
9. Neusoft Becomes First Global Growth Company Partner of World Economic Forum
10. Statement of Eli Lilly and Company on Dr. David Egilman Settlement:
11. Exponent to Present at the Upcoming Sidoti & Company Investor Forum and William Blair Small-Cap Growth Stock Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/23/2017)... ... 23, 2017 , ... Arizona Spine & Joint Hospital ... designation of High Performing Hospitals by U.S. News & World Report for knee replacement ... significantly better than the national average in a given procedure or condition.  , ...
(Date:8/23/2017)... ... August 23, 2017 , ... Virsys12, ... strategic growth plans, announcing the hiring of Kevin Keelan as a Senior Account ... seasoned sales manager, Keelan will be working with Virsys12 senior leadership to extend ...
(Date:8/22/2017)... ... August 22, 2017 , ... ... unique masks and serums that perfectly fuse the beauty of naturally derived ingredients ... 2017 Indie Beauty Expo on August 23rd & 24th in New York City. ...
(Date:8/22/2017)... ... August 22, 2017 , ... Pivot Point Consulting, ... Zack Tisch as the firm’s new Consulting Services Executive. Mr. Tisch will oversee ... accounts, from assisting clients with initial vendor selection and pre-implementation planning through go-live ...
(Date:8/22/2017)... ... ... is new to the Texas market, but is proudly managed by widely recognized All Star ... in Grand Prairie, TX, located in the center of the DFW Metroplex, the fourth largest ... the past 40 years with 32 convenient locations in Texas, Nevada and California resulting in ...
Breaking Medicine News(10 mins):
(Date:8/14/2017)... and PETACH TIKVAH, Israel , Aug. ... a leading developer of adult stem cell technologies for ... ending June 30, 2017. ... for our pivotal Phase 3 trial to investigate NurOwn ... President and Chief Executive Officer of BrainStorm. "We have ...
(Date:8/8/2017)... 8, 2017  BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage ... its financial results for the second quarter ended June ... second quarter 2017 and to date: ... programs for the Company,s lead project, BL-8040: ... with BL-8040 as novel stem cell mobilization treatment for ...
(Date:8/7/2017)... 2017 Zimmer Biomet Holdings, Inc. (NYSE and SIX: ... its Board of Directors has approved the payment of a ... 2017. The cash dividend ... October 27, 2017 to stockholders of record as of the ... dividends are subject to approval of the Board of Directors ...
Breaking Medicine Technology: